Pipeline
Pipeline
R&D Pipelines
Advancing regenerative medicine through innovative homeoprotein targeting therapies.
R&D Pipelines
Advancing regenerative medicine through innovative homeoprotein targeting therapies.
Therapeutic Platform Targeting Homeoproteins (HPs)
Advancing innovative therapies through two complementary strategies
to restore tissue function and unlock natural regeneration.
Strategy 01
Remove Bad HPs
Neutralizing harmful HPs
that accumulate after tissue injury
and suppress endogenous
regeneration pathways.
- CLZ001: Wet-AMD
- CLZ002: Retinitis Pigmentosa
- CLZ003: Dry-AMD
- CLZ004: Alzheimer’s Disease
Strategy 02
Provide Good HPs
Delivering essential regenerative HPs
to tissues degenerating due to
HP deficiencies.
- CLZ005: Muscle Regeneration
- CLZ006: Hair Cell Regeneration
- CLZ007: Corneal Regeneration
Therapeutic Platform Targeting Homeoproteins (HPs)
Advancing innovative therapies through
two complementary strategies
to restore tissue function and unlock
natural regeneration.
Strategy 01
Remove Bad HPs
Neutralizing harmful HPs
that accumulate after tissue injury
and suppress endogenous
regeneration pathways.
- CLZ001: Wet-AMD
- CLZ002: Retinitis Pigmentosa
- CLZ003: Dry-AMD
- CLZ004: Alzheimer’s Disease
Strategy 02
Provide Good HPs
Delivering essential regenerative HPs to tissues degenerating due to HP deficiencies.
- CLZ005: Muscle Regeneration
- CLZ006: Hair Cell Regeneration
- CLZ007: Corneal Regeneration
Research & Development Pipeline
Advancing regenerative medicine through innovative homeoprotein-based therapies.
CLZ001
Wet-type Age-related
Macular Degeneration
(Wet-AMD)
Lead Optimization
Optimizing candidate antibody for preclinical development.
40%
CLZ002
Retinitis Pigmentosa
(RP)
Preclinical
Large animal efficacy tests &
GLP-toxicity tests prior to IND filing
for first-in-human clinical trials
60%
CLZ003
Dry-type Age-related
Macular Degeneration
(Dry-AMD)
Target Validation
Identifying and validating
initial antibody hits.
30%
CLZ004
Alzheimer’s
Disease
Hit-to-read
Validating target and biological
mechanism in disease models
30%
CLZ005
Muscle
Regeneration
Target Validation
Identifying and validating
initial antibody hits.
20%
CLZ006
Hair Cell
Regeneration
Target Validation
Identifying and validating
initial antibody hits.
20%
CLZ007
Corneal
Regeneration
Target Validation
Identifying and validating
initial antibody hits.
20%
Research & Development Pipeline
Advancing regenerative medicine through innovative homeoprotein-based therapies.
CLZ001
Wet-type Age-related Macular Degeneration(Wet-AMD)
Lead Optimization
Optimizing candidate antibody for preclinical development.
40%
CLZ002
Retinitis Pigmentosa(RP)
Preclinical
Large animal efficacy tests &
GLP-toxicity tests prior to IND filing for first-in-human clinical trials
60%
CLZ003
Dry-type Age-related Macular Degeneration (Dry-AMD)
Target Validation
Identifying and validating
initial antibody hits.
30%
CLZ004
Alzheimer’s Disease
Hit-to-read
Validating target and biological
mechanism in disease models
30%
CLZ005
Muscle Regeneration
Target Validation
Identifying and validating
initial antibody hits.
20%
CLZ006
Hair Cell Regeneration
Target Validation
Identifying and validating
initial antibody hits.
20%
CLZ007
Corneal Regeneration
Target Validation
Identifying and validating
initial antibody hits.
20%
Expanding Scalable Horizons
Celliaz is building a scalable regenerative medicine platform with applications spanning ophthalmology, neurodegeneration,
and future tissue regeneration opportunities.
Our proprietary technologies and global intellectual property portfolio provide a strong foundation for future licensing,
co-development, and strategic partnerships.
Ophthalmology
Core Therapeutic Area
Neurodegenerative Diseases
Expansion Area
Strategic Partnerships
Global Business
Expanding Scalable Horizons
Celliaz is building a scalable regenerative medicine platform with applications spanning ophthalmology, neurodegeneration,
and future tissue regeneration opportunities.
Our proprietary technologies and global intellectual property portfolio provide a strong foundation for future licensing,
co-development, and strategic partnerships.
Ophthalmology
Core Therapeutic Area
Neurodegenerative Diseases
Expansion Area
Strategic Partnerships
Global Business